{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T13:39:05Z","timestamp":1776605945874,"version":"3.51.2"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42177417"],"award-info":[{"award-number":["42177417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004863","name":"Zhejiang Chinese Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["B07023"],"award-info":[{"award-number":["B07023"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bmcl.2026.130563","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:35:00Z","timestamp":1769560500000},"page":"130563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combined antitumor efficacy of a new tanshinone IIA analog and irinotecan with alleviating gastrointestinal side effect"],"prefix":"10.1016","volume":"135","author":[{"given":"Junfeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Mang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengtao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoyin","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bmcl.2026.130563_bb0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality","volume":"66","author":"Arnold","year":"2017","journal-title":"Gut"},{"issue":"10207","key":"10.1016\/j.bmcl.2026.130563_bb0010","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.bmcl.2026.130563_bb0015","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.32163","article-title":"Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer","volume":"125","author":"Piawah","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bmcl.2026.130563_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.semcdb.2019.05.018","article-title":"Metabolic pathways regulating colorectal cancer initiation and progression","volume":"98","author":"La Vecchia","year":"2020","journal-title":"Semin Cell Dev Biol"},{"issue":"9927","key":"10.1016\/j.bmcl.2026.130563_bb0025","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130563_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/1040-8428(96)00211-9","article-title":"The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996","volume":"24","author":"O\u2019Reilly","year":"1996","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130563_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/1040-8428(96)00201-6","article-title":"Irinotecan (CPT-11): pharmacology and clinical applications","volume":"24","author":"Masuda","year":"1996","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bmcl.2026.130563_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol Res"},{"issue":"1 Suppl 3","key":"10.1016\/j.bmcl.2026.130563_bb0045","first-page":"3","article-title":"Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins","volume":"23","author":"Pommier","year":"1996","journal-title":"Semin Oncol"},{"issue":"16","key":"10.1016\/j.bmcl.2026.130563_bb0050","first-page":"4187","article-title":"Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato","year":"1991","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130563_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3747\/co.2007.96","article-title":"Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian working group on chemotherapy-induced diarrhea","volume":"14","author":"Maroun","year":"2007","journal-title":"Curr Oncol"},{"issue":"14","key":"10.1016\/j.bmcl.2026.130563_bb0060","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmcl.2026.130563_bb0065","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/0959-8049(96)00293-6","article-title":"Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective","volume":"32","author":"Bleiberg","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmcl.2026.130563_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109142","article-title":"Natural products for treating colorectal cancer: a mechanistic review","volume":"117","author":"Huang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2026.130563_bb0075","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.2147\/DDDT.S266911","article-title":"Pharmacological activity and mechanism of tanshinone IIA in related diseases","volume":"14","author":"Guo","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130563_bb0080","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.atherosclerosis.2013.07.005","article-title":"Regulation of antioxidant system, lipids and fatty acid \u03b2-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats","volume":"230","author":"Wei","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130563_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/emm.2005.18","article-title":"Cryptotanshinone but not tanshinone IIA inhibits angiogenesisin vitro","volume":"37","author":"Hur","year":"2005","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bmcl.2026.130563_bb0090","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7916763","article-title":"Tanshinone IIA protects against dextran sulfate sodium- (DSS-) induced colitis in mice by modulation of neutrophil infiltration and activation","volume":"2016","author":"Liu","year":"2016","journal-title":"Oxidative Med Cell Longev"},{"key":"10.1016\/j.bmcl.2026.130563_bb0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2174\/138920007780655450","article-title":"Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge","volume":"8","author":"Yu","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.bmcl.2026.130563_bb0100","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130563_bb0105","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl) glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130563_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3835(01)00718-2","article-title":"Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells","volume":"175","author":"Zuco","year":"2002","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130563_bb0115","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1535-7163.MCT-05-0425","article-title":"Low doses of cisplatin or gemcitabine plus photofrin\/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299)","volume":"5","author":"Crescenzi","year":"2006","journal-title":"Mol Cancer Ther"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T12:47:34Z","timestamp":1776602854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"alternative-id":["S0960894X26000302"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130563","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined antitumor efficacy of a new tanshinone IIA analog and irinotecan with alleviating gastrointestinal side effect","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130563"}}